ATE369894T1 - Kombination enthaltend ein mittel zur verminderung von vegf-aktivität und ein mittel zur verminderung von egf-aktivität - Google Patents

Kombination enthaltend ein mittel zur verminderung von vegf-aktivität und ein mittel zur verminderung von egf-aktivität

Info

Publication number: ATE369894T1
Authority: AT; Austria
Prior art keywords: agent; reducing; activity; egf; combination
Prior art date: 2000-11-22

Application number

AT01997301T

Other languages

English (en)

Inventor

Jeanette Wood

Ralf Brandt

Guido Bold

Peter Traxler

Original Assignee

Novartis Pharma Gmbh

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-11-22

Filing date

2001-11-20

Publication date

2007-09-15

2000-11-22 Priority claimed from GB0028467A external-priority patent/GB0028467D0/en

2001-09-10 Priority claimed from GB0121813A external-priority patent/GB0121813D0/en

2001-11-20 Application filed by Novartis Pharma Gmbh filed Critical Novartis Pharma Gmbh

2007-09-15 Application granted granted Critical

2007-09-15 Publication of ATE369894T1 publication Critical patent/ATE369894T1/de

Links

230000000694 effects Effects 0.000 title abstract 3
239000003795 chemical substances by application Substances 0.000 title 2
102000005789 Vascular Endothelial Growth Factors Human genes 0.000 title 1
108010019530 Vascular Endothelial Growth Factors Proteins 0.000 title 1
239000003638 chemical reducing agent Substances 0.000 title 1
239000004480 active ingredient Substances 0.000 abstract 2
201000010099 disease Diseases 0.000 abstract 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
230000033115 angiogenesis Effects 0.000 abstract 1
150000001875 compounds Chemical class 0.000 abstract 1
230000007423 decrease Effects 0.000 abstract 1
230000002074 deregulated effect Effects 0.000 abstract 1
238000000034 method Methods 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1
230000002062 proliferating effect Effects 0.000 abstract 1
VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Epidemiology (AREA)
Diabetes (AREA)
Immunology (AREA)
Hematology (AREA)
Neurology (AREA)
Urology & Nephrology (AREA)
Oncology (AREA)
Molecular Biology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Pain & Pain Management (AREA)
Obesity (AREA)
Rheumatology (AREA)
Psychiatry (AREA)
Vascular Medicine (AREA)
Emergency Medicine (AREA)
Endocrinology (AREA)
Hospice & Palliative Care (AREA)
Ophthalmology & Optometry (AREA)
Transplantation (AREA)
Gastroenterology & Hepatology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

AT01997301T 2000-11-22 2001-11-20 Kombination enthaltend ein mittel zur verminderung von vegf-aktivität und ein mittel zur verminderung von egf-aktivität ATE369894T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GB0028467A GB0028467D0 (en)	2000-11-22	2000-11-22	Use of organic compounds
GB0121813A GB0121813D0 (en)	2001-09-10	2001-09-10	Organic compounds

Publications (1)

Publication Number	Publication Date
ATE369894T1 true ATE369894T1 (de)	2007-09-15

Family

ID=26245316

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT01997301T ATE369894T1 (de)	2000-11-22	2001-11-20	Kombination enthaltend ein mittel zur verminderung von vegf-aktivität und ein mittel zur verminderung von egf-aktivität

Country Status (10)

Country	Link
US (2)	US20040034026A1 (de)
EP (2)	EP1339458B1 (de)
JP (1)	JP2004513964A (de)
AT (1)	ATE369894T1 (de)
AU (1)	AU2002223684A1 (de)
CA (1)	CA2427184A1 (de)
DE (1)	DE60130017T2 (de)
ES (1)	ES2290199T3 (de)
PT (1)	PT1339458E (de)
WO (1)	WO2002041882A2 (de)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
HK1044769B (zh)	1999-06-21	2005-02-25	贝林格尔英格海姆法玛两合公司	雙環雜環化合物，含有該化合物的藥物組合物，該化合物的用途及其製備方法
AU9598601A (en)	2000-10-20	2002-04-29	Eisai Co Ltd	Nitrogenous aromatic ring compounds
US7019012B2 (en)	2000-12-20	2006-03-28	Boehringer Ingelheim International Pharma Gmbh & Co. Kg	Quinazoline derivatives and pharmaceutical compositions containing them
EP1441736A2 (de) *	2001-10-29	2004-08-04	Novartis AG	Verwendung von 7h-pyrrolo[2,3-d]pyrimidinderivaten in der behandlung solider tumore
WO2003059354A2 (en) *	2001-12-21	2003-07-24	Bayer Pharmaceuticals Corporation	Anti-angiogenesis combination therapies comprising pyridazine or pyridine derivatives
US6924285B2 (en)	2002-03-30	2005-08-02	Boehringer Ingelheim Pharma Gmbh & Co.	Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them
DE10221018A1 (de)	2002-05-11	2003-11-27	Boehringer Ingelheim Pharma	Verwendung von Hemmern der EGFR-vermittelten Signaltransduktion zur Behandlung von gutartiger Prostatahyperplasie (BPH)/Prostatahypertrophie
WO2004002485A1 (en) *	2002-06-28	2004-01-08	Novartis Ag	Combination comprising a vasculostatic compound and an alkylating agent for the treatmemt of a tumor
US7642252B2 (en) *	2002-07-22	2010-01-05	Chemgenex Pharmaceuticals, Inc.	Angiogenesis inhibition by cephalotaxine alkaloids, derivatives, compositions and uses thereof
GB0218526D0 (en) *	2002-08-09	2002-09-18	Astrazeneca Ab	Combination therapy
GB0223341D0 (en) *	2002-10-08	2002-11-13	Groningen Acad Ziekenhuis	Organic compounds
ATE508747T1 (de)	2003-03-10	2011-05-15	Eisai R&D Man Co Ltd	C-kit kinase-hemmer
GB0316127D0 (en) *	2003-07-10	2003-08-13	Astrazeneca Ab	Combination therapy
GB0317665D0 (en)	2003-07-29	2003-09-03	Astrazeneca Ab	Qinazoline derivatives
ES2314444T3 (es)	2003-08-29	2009-03-16	Pfizer Inc.	Tienopiridina-fenilacetaminasy sus derivados utiles como nuevos agentes antiangiogenicos.
ATE395346T1 (de)	2003-09-16	2008-05-15	Astrazeneca Ab	Chinazolinderivate als tyrosinkinaseinhibitoren
ES2279441T3 (es) *	2003-09-19	2007-08-16	Astrazeneca Ab	Derivados de quinazolina.
GB0322409D0 (en)	2003-09-25	2003-10-29	Astrazeneca Ab	Quinazoline derivatives
US7683172B2 (en)	2003-11-11	2010-03-23	Eisai R&D Management Co., Ltd.	Urea derivative and process for preparing the same
GB0326459D0 (en)	2003-11-13	2003-12-17	Astrazeneca Ab	Quinazoline derivatives
AU2004309166B2 (en)	2003-12-23	2008-02-21	Pfizer Inc.	Novel quinoline derivatives
DE602005010824D1 (de)	2004-02-03	2008-12-18	Astrazeneca Ab	Chinazolinderivate
FR2865733B1 (fr) *	2004-02-04	2007-10-12	Merck Sante Sas	Derives de thiazolylimidazole, leurs procedes de preparation, les compositions pharmaceutiques qui les contiennent et leurs applications en medecine
GB0406445D0 (en) *	2004-03-23	2004-04-28	Astrazeneca Ab	Combination therapy
MXPA06015237A (es)	2004-06-29	2007-12-10	Amgen Inc	Pirrolo[2-3-d]pirimidinas que modulan la actividad de ack1 y lck.
JP2008508358A (ja) *	2004-08-02	2008-03-21	オーエスアイ・ファーマスーティカルズ・インコーポレーテッド	アリール−アミノ置換ピロロピリミジンマルチキナーゼ阻害化合物
ATE428421T1 (de)	2004-09-17	2009-05-15	Eisai R&D Man Co Ltd	Medizinische zusammensetzung mit verbesserter stabilität und reduzierten gelierungseigenschaften
JO2596B1 (en) *	2004-11-30	2011-02-27	نوفارتيس ايه جي	Compositions include epothelones and tyrosine protein kinase inhibitors and their pharmaceutical uses
WO2007015569A1 (ja) *	2005-08-01	2007-02-08	Eisai R & D Management Co., Ltd.	血管新生阻害物質の効果を予測する方法
JP4989476B2 (ja) *	2005-08-02	2012-08-01	エーザイ・アール・アンド・ディー・マネジメント株式会社	血管新生阻害物質の効果を検定する方法
CA2620594C (en) *	2005-09-01	2012-08-21	Eisai R&D Management Co., Ltd.	Pharmaceutical composition having improved disintegratability
AU2006309551B2 (en)	2005-11-07	2012-04-19	Eisai R & D Management Co., Ltd.	Use of combination of anti-angiogenic substance and c-kit kinase inhibitor
JP5688877B2 (ja)	2005-11-11	2015-03-25	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	癌疾患の治療用キナゾリン誘導体
EP1964837A4 (de) *	2005-11-22	2010-12-22	Eisai R&D Man Co Ltd	Antitumormittel gegen multiples myelom
JP2009120486A (ja) *	2005-12-05	2009-06-04	Mitsubishi Pharma Corp	核内オーファン受容体の新規活性化剤及びその用途
CN104706637A (zh) *	2006-05-18	2015-06-17	卫材R&D管理有限公司	针对甲状腺癌的抗肿瘤剂
JPWO2008001956A1 (ja) *	2006-06-29	2009-12-03	エーザイ・アール・アンド・ディー・マネジメント株式会社	肝線維症治療剤
WO2008026748A1 (en)	2006-08-28	2008-03-06	Eisai R & D Management Co., Ltd.	Antitumor agent for undifferentiated gastric cancer
AU2007299080B2 (en)	2006-09-18	2013-04-18	Boehringer Ingelheim International Gmbh	Method for treating cancer harboring EGFR mutations
EP1921070A1 (de)	2006-11-10	2008-05-14	Boehringer Ingelheim Pharma GmbH & Co. KG	Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstelllung
CA2676796C (en)	2007-01-29	2016-02-23	Eisai R & D Management Co., Ltd.	Composition for treatment of undifferentiated gastric cancer
AU2008212999A1 (en)	2007-02-06	2008-08-14	Boehringer Ingelheim International Gmbh	Bicyclic heterocycles, drugs containing said compounds, use thereof, and method for production thereof
MX2009013332A (es)	2007-06-08	2010-01-25	Mannkind Corp	Inhibidores de ire-1 alfa.
US8952035B2 (en)	2007-11-09	2015-02-10	Eisai R&D Management Co., Ltd.	Combination of anti-angiogenic substance and anti-tumor platinum complex
KR101506062B1 (ko) *	2008-01-29	2015-03-25	에자이 알앤드디 매니지먼트 가부시키가이샤	혈관 저해 물질과 탁산의 병용
US8497369B2 (en)	2008-02-07	2013-07-30	Boehringer Ingelheim International Gmbh	Spirocyclic heterocycles medicaments containing said compounds, use thereof and method for their production
DE102008021699A1 (de)	2008-04-25	2009-10-29	Schebo Biotech Ag	Neue Pyrrolopyrimidin-Derivate und deren Verwendung
EP2313397B1 (de)	2008-08-08	2016-04-20	Boehringer Ingelheim International GmbH	Cyclohexyloxy-substituierte heterocyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
PT2451445T (pt)	2009-07-06	2019-07-10	Boehringer Ingelheim Int	Processo para secagem de bibw2992, dos seus sais e de formulações farmacêuticas sólidas compreendendo este ingrediente ativo
MY162940A (en)	2009-08-19	2017-07-31	Eisai R&D Man Co Ltd	Quinoline derivative-containing pharmaceutical composition
CN102548554B (zh) *	2009-08-31	2014-04-23	浦项工科大学校产学协力团	通过抑制血管内皮生长因子受体治疗Th17炎症疾病的方法以及用于此方法的药物组合物
WO2011035540A1 (zh)	2009-09-28	2011-03-31	齐鲁制药有限公司	作为酪氨酸激酶抑制剂的4-（取代苯胺基）喹唑啉衍生物
CN102958523B (zh)	2010-06-25	2014-11-19	卫材R&D管理有限公司	使用具有激酶抑制作用的组合的抗肿瘤剂
CN103402519B (zh)	2011-04-18	2015-11-25	卫材R&D管理有限公司	肿瘤治疗剂
JP6038128B2 (ja)	2011-06-03	2016-12-07	エーザイ・アール・アンド・ディー・マネジメント株式会社	レンバチニブ化合物に対する甲状腺癌対象及び腎臓癌対象の反応性を予測及び評価するためのバイオマーカー
EP2752413B1 (de)	2012-03-26	2016-03-23	Fujian Institute Of Research On The Structure Of Matter, Chinese Academy Of Sciences	Chinazolinderivat und anwendung davon
KR20150098605A (ko)	2012-12-21	2015-08-28	에자이 알앤드디 매니지먼트 가부시키가이샤	퀴놀린 유도체의 비정질 형태 및 그의 제조방법
NZ714049A (en)	2013-05-14	2020-05-29	Eisai R&D Man Co Ltd	Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds
US9242965B2 (en)	2013-12-31	2016-01-26	Boehringer Ingelheim International Gmbh	Process for the manufacture of (E)-4-N,N-dialkylamino crotonic acid in HX salt form and use thereof for synthesis of EGFR tyrosine kinase inhibitors
PT3524595T (pt)	2014-08-28	2022-09-19	Eisai R&D Man Co Ltd	Derivado de quinolina altamente puro e método para produção do mesmo
LT3263106T (lt)	2015-02-25	2024-01-10	Eisai R&D Management Co., Ltd.	Chinolino darinių kartumo sumažinimo būdas
KR102662228B1 (ko)	2015-03-04	2024-05-02	머크 샤프 앤드 돔 코포레이션	암을 치료하기 위한 pd-1 길항제 및 vegfr/fgfr/ret 티로신 키나제 억제제의 조합
MX373231B (es)	2015-06-16	2020-05-08	Eisai R&D Man Co Ltd	Agente anticancerigeno.
US12220398B2 (en)	2015-08-20	2025-02-11	Eisai R&D Management Co., Ltd.	Tumor therapeutic agent
US12303505B2 (en)	2017-02-08	2025-05-20	Eisai R&D Management Co., Ltd.	Tumor-treating pharmaceutical composition
RU2019134940A (ru)	2017-05-16	2021-06-16	Эйсай Ар Энд Ди Менеджмент Ко., Лтд.	Лечение гепатоцеллюлярной карциномы

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0739203A4 (de) *	1994-01-14	2000-12-20	Cell Therapeutics Inc	Verfahren zur behandlung von erkrankungen, die durch zellproliferation als antwort auf pdgf, egf, fgf und vegf vermittelt werden
US5747498A (en) *	1996-05-28	1998-05-05	Pfizer Inc.	Alkynyl and azido-substituted 4-anilinoquinazolines
US5731325A (en) *	1995-06-06	1998-03-24	Andrulis Pharmaceuticals Corp.	Treatment of melanomas with thalidomide alone or in combination with other anti-melanoma agents
SI9620103A (sl) *	1995-07-06	1998-10-31	Novartis Ag	Pirolopirimidini in postopki za njihovo pripravo
CO4950519A1 (es) *	1997-02-13	2000-09-01	Novartis Ag	Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion
CO4940430A1 (es) *	1997-07-07	2000-07-24	Novartis Ag	Compuestos policiclicos que contienen estaurosporina hidrogenada con propiedades farmacologicas convenientes y un efecto inhibidor sobre el crecimiento de las celulas tumorales
AU4427199A (en) *	1998-06-26	2000-01-17	Georgetown University	Inhibitors of phosphatidyl (myo)-inositol cycle
CN1660840A (zh) *	1999-03-30	2005-08-31	诺瓦提斯公司	治疗炎性疾病的酞嗪衍生物
ITMI992711A1 (it) *	1999-12-27	2001-06-27	Novartis Ag	Composti organici

2001
- 2001-11-20 AT AT01997301T patent/ATE369894T1/de not_active IP Right Cessation
- 2001-11-20 EP EP01997301A patent/EP1339458B1/de not_active Expired - Lifetime
- 2001-11-20 DE DE60130017T patent/DE60130017T2/de not_active Expired - Lifetime
- 2001-11-20 CA CA002427184A patent/CA2427184A1/en not_active Abandoned
- 2001-11-20 PT PT01997301T patent/PT1339458E/pt unknown
- 2001-11-20 ES ES01997301T patent/ES2290199T3/es not_active Expired - Lifetime
- 2001-11-20 EP EP07108093A patent/EP1810715A3/de not_active Withdrawn
- 2001-11-20 JP JP2002544061A patent/JP2004513964A/ja active Pending
- 2001-11-20 US US10/432,303 patent/US20040034026A1/en not_active Abandoned
- 2001-11-20 WO PCT/EP2001/013441 patent/WO2002041882A2/en not_active Ceased
- 2001-11-20 AU AU2002223684A patent/AU2002223684A1/en not_active Abandoned
2006
- 2006-08-02 US US11/498,027 patent/US20060270665A1/en not_active Abandoned

Also Published As

Publication number	Publication date
DE60130017T2 (de)	2008-05-15
US20060270665A1 (en)	2006-11-30
JP2004513964A (ja)	2004-05-13
EP1339458B1 (de)	2007-08-15
EP1810715A3 (de)	2009-12-16
CA2427184A1 (en)	2002-05-30
EP1339458A2 (de)	2003-09-03
AU2002223684A1 (en)	2002-06-03
WO2002041882A3 (en)	2002-09-06
DE60130017D1 (de)	2007-09-27
WO2002041882A2 (en)	2002-05-30
US20040034026A1 (en)	2004-02-19
PT1339458E (pt)	2007-11-09
ES2290199T3 (es)	2008-02-16
EP1810715A2 (de)	2007-07-25

Legal Events

Date

Code

Title

Description

2007-12-15

UEP

Publication of translation of european patent specification

Ref document number: 1339458

Country of ref document: EP

2011-08-15

REN

Ceased due to non-payment of the annual fee

Publication	Publication Date	Title
ATE369894T1 (de)	2007-09-15	Kombination enthaltend ein mittel zur verminderung von vegf-aktivität und ein mittel zur verminderung von egf-aktivität
DE60043587D1 (de)	2010-02-04	Mittel für erkrankungen assoziert mit knochensubstanzverlust
ATE361084T1 (de)	2007-05-15	Topische pharmazeutische zusammensetzungen mit proanthocyanidinen, glycyrrhetinic säure und telmesteine zur behandlung von dermatitis
DE60143360D1 (de)	2010-12-09	Zusammensetzung zur transdermalen und/oder transmukosalen Verabreichung von Wirkstoffen, die ausreichende therapeutische Spiegel garantiert
EP1226109A4 (de)	2005-01-26	Phenylamin-carbonsäure-verbindungen und zubereitungen zur verabreichung von wirkstoffen
WO2003099771A3 (en)	2004-04-01	Diaryl urea derivatives useful for the treatment of protein kinase dependent diseases
DE60235083D1 (de)	2010-03-04	Substituierte tetracyclin-verbindungen zur behandlung von malaria
EP1408945A4 (de)	2005-07-06	Verfahren, verbindungen und zusammensetzungen zur reduzierung von körperfett und zur modulierung des fettsäurestoffwechsels
DE69530926D1 (de)	2003-07-03	Mittel zur förderung des haarwachstums
HU0102039D0 (en)	2001-07-30	Use of paclitaxel stabilized with albumin for the preparation of pharmaceutical compositions treating solid tumors and the pharmaceutical compositions obtained thereby
IS5591A (is)	2000-08-18	Grunnmassaprótínsamsetningar til sáragræðslu
HK1045816A1 (zh)	2002-12-13	角质细胞生长因子-2制剂
ATE322878T1 (de)	2006-04-15	Biotin enthaltende galenische formulierung
ATE304373T1 (de)	2005-09-15	Nervenschutzmittel
ATE439833T1 (de)	2009-09-15	Pharmazeutische zubereitung enthaltend ein catechin, ascorbinsäure, prolin und lysin zur behandlung von neoplastischen krankheiten
DE60134234D1 (de)	2008-07-10	Nukleinsäurekonstrukte, damit transformierte vaskuläre zellen, pharmezeutische zusammensetzungen und verfahren zur induktion der angiogenese
FR2831059B1 (fr)	2004-07-23	Utilisation des fructo-oligosaccharides comme actifs cosmetiques, compositions les comprenant et procede de conservation les utilisant
DE60238395D1 (de)	2011-01-05	Ess-protein und verfahren zur verwendung davon
WO2004052331A3 (fr)	2004-08-12	Utilisation d'un extrait de miellat de coton comme ingredient acitif
WO2003040119A8 (fr)	2003-11-27	Inhibiteurs de l'angiogenese
ATE224730T1 (de)	2002-10-15	Mittel zur behandlung von pigmentierungsstörungen
IL160160A0 (en)	2004-07-25	SUBSTITUTED 5,6,6a, 11b-TETRAHYDRO-7-OXA-5-AZA-BENZO[c]FLUORENE-6-CARBOXYLIC ACID DERIVATIVES SERVING AS NMDA ANTAGONISTS
BR0312283A (pt)	2005-04-12	Combinação compreendendo um agente de alquilação e um agente redutor da atividade de vegf
ATE446755T1 (de)	2009-11-15	Antihelmintika zur verhinderung von parasitären infektionen bei mensch und tier
ATE329613T1 (de)	2006-07-15	Wachstumhormone inhibitoren enthaltende pharmazeutische zubereitungen oder ihre biologisch aktive fragmente zur behandlung von uterinen myomas